PURPOSE: To review our initial experience with the holmium laser in patients with recurrent superficial bladder cancer. PATIENTS AND METHODS: We treated 41 patients having 71 recurrent superficial transitional-cell tumors of the bladder between December 1994 and September 1997 using the holmium:YAG laser under local anesthesia. The laser treatment was carried out as a part of the follow-up flexible cystoscopy protocol, and topical anesthesia was used. The mean follow-up was 14 months (range 3-33 months). RESULTS: There were 13 recurrent tumors in the treated area and 38 recurrences in the untreated areas. Of interest, a subgroup of 10 patients were treated before 1994 with cystodiathermy and later on with the holmium:YAG laser at various times during their follow-up. The local recurrence rate with cystodiathermy was 32% compared with 10% after laser treatment (P = 0.39). A questionnaire study of 33 patients showed complete satisfaction with the treatment. Only 2 (6%) elected to have a further procedure under general anesthesia. In the series, 83% scored their pain as 2 or less of 10 on a visual analog scale. CONCLUSIONS: The absence of complications, high patient satisfaction, and ability to be used in the outpatient setting make the holmium:YAG laser an attractive alternative in the treatment of recurrent superficial cancer of the bladder.
PURPOSE: To review our initial experience with the holmium laser in patients with recurrent superficial bladder cancer. PATIENTS AND METHODS: We treated 41 patients having 71 recurrent superficial transitional-cell tumors of the bladder between December 1994 and September 1997 using the holmium:YAG laser under local anesthesia. The laser treatment was carried out as a part of the follow-up flexible cystoscopy protocol, and topical anesthesia was used. The mean follow-up was 14 months (range 3-33 months). RESULTS: There were 13 recurrent tumors in the treated area and 38 recurrences in the untreated areas. Of interest, a subgroup of 10 patients were treated before 1994 with cystodiathermy and later on with the holmium:YAG laser at various times during their follow-up. The local recurrence rate with cystodiathermy was 32% compared with 10% after laser treatment (P = 0.39). A questionnaire study of 33 patients showed complete satisfaction with the treatment. Only 2 (6%) elected to have a further procedure under general anesthesia. In the series, 83% scored their pain as 2 or less of 10 on a visual analog scale. CONCLUSIONS: The absence of complications, high patient satisfaction, and ability to be used in the outpatient setting make the holmium:YAG laser an attractive alternative in the treatment of recurrent superficial cancer of the bladder.
Authors: Mehmet A Kosoglu; Robert L Hood; John H Rossmeisl; David C Grant; Yong Xu; John L Robertson; Marissa Nichole Rylander; Christopher G Rylander Journal: Lasers Surg Med Date: 2011-11 Impact factor: 4.025
Authors: R Lyle Hood; William F Carswell; Amanda Rodgers; Mehmet A Kosoglu; Marissa Nichole Rylander; David Grant; John L Robertson; Christopher G Rylander Journal: Lasers Med Sci Date: 2012-10-04 Impact factor: 3.161
Authors: Mathias Wolters; Mario W Kramer; Jan U Becker; Matthias Christgen; Udo Nagele; Florian Imkamp; Martin Burchardt; Axel S Merseburger; Markus A Kuczyk; Thorsten Bach; Andreas J Gross; Thomas R W Herrmann Journal: World J Urol Date: 2011-05-08 Impact factor: 4.226
Authors: Mario W Kramer; Thorsten Bach; Mathias Wolters; Florian Imkamp; Andreas J Gross; Markus A Kuczyk; Axel S Merseburger; Thomas R W Herrmann Journal: World J Urol Date: 2011-05-05 Impact factor: 4.226
Authors: Mario W Kramer; Mathias Wolters; Hannes Cash; Stephan Jutzi; Florian Imkamp; Markus A Kuczyk; Axel S Merseburger; Thomas R W Herrmann Journal: World J Urol Date: 2014-06-17 Impact factor: 4.226